RhythmX AI has launched itself with $50 million in funding and support from investment company SAIGroup to build a generative AI platform to deliver personalised health care for patients with chronic and long term health conditions.

The company’s platform equips doctors with generative AI capabilities and predictive AI algorithms based on longitudinal health data.  These provide patient-specific prescriptive actions and recommendations doctors can drill into using a generative AI-enabled natural language interface and AI-native copilots.

RhythmX AI’s platform is designed to work in concert with existing healthcare systems. The data and rationale behind AI-enabled recommendations are explained, summarised, and presented in a single workflow. RhythmX AI’s models will tap into various assets of SAIGroup including longitudinal data related to 300 million patients, more than 4.4 billion total annual claims, and more than 1.8 million healthcare professionals at more than 300 thousand facilities. The company will continue to expand its network of data sources as the range of chronic and acute conditions covered in the platform increases.

SAIGroup’s backing brings to RhythmX AI the resources of portfolio companies SymphonyAI and ConcertAI. ConcertAI is a specialist in real-world data and enterprise AI for life sciences and healthcare. SymphonyAI is a specialist in enterprise AI for vertical sectors, including retail, financial services, manufacturing, media, and IT.

RhythmX AI will use SAIGroup’s Eureka AI platform, which supports AI solutions for thousands of customers including Fortune 500 companies. EurekaAI uses unsupervised, supervised, and semi-supervised machine learning techniques to uncover new insights and predictions. Worldwide, 35 of the top life sciences companies, nine of the top 10 oncology companies, and more than 900 healthcare providers use EurekaAI-based solutions.

“It’s time to apply AI to the massive challenges doctors and hospital systems face in providing the best treatments for patients,” said Dr. Romesh Wadhwani, founder and CEO of SAIGroup and recently honoured on the inaugural TIME100 AI list. “SAIGroup’s strategy of combining deep domain expertise with advanced AI has a successful track record with SymphonyAI and ConcertAI and will do the same with RhythmX AI. The rapidly growing team at RhythmX AI has the right assets, data, AI expertise, and the right capital and leadership to solve these barriers.”

“Providing the right care at the right time to the right patient is more challenging than ever,” said RhythmX AI CEO Deepthi Bathina, former chief clinical product officer at Humana. “Chronic conditions absorb nearly 90% of healthcare spending in the U.S. That’s exacerbated by a shortage of physicians who in turn face increasingly high expectations to deliver integrated care above and beyond their current load. This is where we need to focus new AI technologies, as we help doctors operate at the top of their license each day.”

RhythmX AI is building a clinical advisory board that includes:

• Gregg Meyer, MD, MSc President of Community Division and Executive Vice President of Value-based Care at Mass General Brigham
• Sunny Bhatia, MD, CEO of Prime Healthcare, Region I, and Corporate Chief Medical Officer for all Prime Health locations
• Jordan Asher, MD, MS, Executive Vice President and Chief Clinical Officer of Sentara Health

“It’s never been more important to support doctors and free them up to deliver the integrated whole-person care which is so difficult to do given how much data needs to be read and processed within seconds,” said Dr. Gregg Meyer, president of community division and executive vice president of value-based care at Mass General Brigham. “Physicians are now considering clinical experience, social determinants, lifestyle factors and mental health factors to deliver on hyper-personalised interventions, especially to patients with rising risk. There is a critical need in the industry for a platform that can aid physicians to solve these issues.”